{"id":390083,"date":"2021-03-10T00:00:00","date_gmt":"2021-03-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2020-biopharma-gastric-cancer-gastroesophageal-junction-adenocarcinoma-and-esophageal-cancer-disease-landscape\/"},"modified":"2026-03-31T10:43:47","modified_gmt":"2026-03-31T10:43:47","slug":"dlsfon0015-2020-biopharma-gastric-cancer-gastroesophageal-junction-adenocarcinoma-and-esophageal-cancer-disease-landscape","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2020-biopharma-gastric-cancer-gastroesophageal-junction-adenocarcinoma-and-esophageal-cancer-disease-landscape\/","title":{"rendered":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma and Esophageal Cancer | Disease Landscape &#038; Forecast | G7 | 2020"},"content":{"rendered":"<p>The incidence of gastroesophageal cancer\u2014encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma\u2014continues to rise; however, treatment options remain limited. Targeted therapies, including Herceptin (Roche \/ Genentech \/ Chugai [for HER2-positive patients only]) and Cyramza (Eli Lilly), have been approved exclusively for gastric and GEJ adenocarcinoma patients across the major markets. Additional agents are also approved for later-line treatments in certain geographies, such as Keytruda (Merck &#038; Co.), Opdivo (Bristol-Myers Squibb), and Lonsurf (Taiho). A plethora of agents including immunotherapies, vaccines, and a variety of targeted therapies are vying for approval in underserved patient segments, such as resectable disease or the first-line metastatic setting.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How do current treatment practices differ among esophageal, gastric, and GEJ cancer patients? Do these practices differ by geography, and which populations provide the greatest drug-treatment opportunities?<\/li>\n<li>What are interviewed experts\u2019 insights on the use of currently approved agents? What clinical needs remain unfulfilled, and on what opportunities can developers capitalize?<\/li>\n<li>Which drugs in late-phase development are poised to change the treatment landscape for gastroesophageal cancer? How are these agents being assessed, and how will they impact the gastroesophageal cancer market?<\/li>\n<li>What are the key market drivers and constraints in the gastroesophageal market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan.<\/p>\n<p>Primary research: 23 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.<\/p>\n<p>Epidemiology: Diagnosed and recurrent incidence of gastroesophageal cancer by country, segmented by HER2 status, histology, stage I-IV, and line of therapy.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2028, segmented by brands \/ generics and market-relevant drug treatable populations.<\/p>\n<p>Emerging therapies: Phase III: 9 drugs; Phase I \/ II: ~30 drugs.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390083","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-esophageal-cancer","biopharma-therapy-areas-gastric-cancer","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390083\/revisions"}],"predecessor-version":[{"id":576437,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390083\/revisions\/576437"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}